MONCYTE Health Secures €1M Seed Funding to Advance Personalized Cardiovascular Treatment

“Securing EUR 1 million seed financing was a significant milestone for MONCYTE Health, supporting our mission to transform cholesterol management with precision diagnostics. The Scius team’s strategic advice and media engagement effectively amplified our funding announcement, increasing visibility among investors, clinicians, and industry leaders.”

Tamara Alagirova, CEO & Founder, MONCYTE Health

Objectives

Raise visibility of MONCYTE Health’s successful EUR 1 million seed financing round.
Position MONCYTE Health as an innovator in personalized cardiovascular disease treatment through its proprietary technology.
Highlight the company’s leadership in leveraging cellular lipid analysis to optimize treatment for high cholesterol.

Strategy

Drafted press release and media pitch.
Pitched select journalists under embargo.
Advised on the LinkedIn post.
Issued English and Finnish versions over GlobeNewsWire and via our GDPR compliant distribution platform.

Results

Secured top-tier international trade media coverage, including Health Tech World, Precision Medicine, FirstWord HealthTech, and MedTech Innovation News.
Additional coverage in investment and startup-focused outlets such as FinSMEs, AIN, and Arctic Startup.
Secured a longer feature piece in Precision Medicine Online.
Published in 15+ online financial and medical news platforms, including BioSpace, Pharmiweb, and Yahoo Finance.
Shared on LinkedIn by multiple industry stakeholders, including Helsinki Innovation Services, BCF International, and Startup Health.